Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xeris Biopharma Holdings, Inc. (XERS) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xeris Biopharma Holdings, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1867096.
Total stock buying since 2021: $1,188,754.
Total stock sales since 2021: $1,674,619.
Total stock option exercises since 2021: $780,275.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 25,000 | $109,474 | 232,232 | $1,647,459 | 47,040 | $313,286 |
| 2024 | 18,700 | $40,313 | 0 | $0 | 235,083 | $459,242 |
| 2023 | 81,639 | $148,662 | 0 | $0 | 0 | $0 |
| 2022 | 120,000 | $169,400 | 11,228 | $27,160 | 11,228 | $7,747 |
| 2021 | 345,000 | $720,905 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 192,232 | $1,430,219 | 47,040 | $313,286 |
| 2025-06 | 25,000 | $109,474 | 0 | $0 | 0 | $0 |
| 2025-03 | 0 | $0 | 40,000 | $217,240 | 0 | $0 |
| 2024-11 | 0 | $0 | 0 | $0 | 19,483 | $30,198 |
| 2024-08 | 8,800 | $20,279 | 0 | $0 | 0 | $0 |
| 2024-05 | 5,400 | $10,314 | 0 | $0 | 0 | $0 |
| 2024-03 | 4,500 | $9,720 | 0 | $0 | 215,600 | $429,044 |
| 2023-11 | 71,639 | $124,872 | 0 | $0 | 0 | $0 |
| 2023-08 | 10,000 | $23,790 | 0 | $0 | 0 | $0 |
| 2022-12 | 20,000 | $29,000 | 0 | $0 | 0 | $0 |
| 2022-05 | 100,000 | $140,400 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 11,228 | $27,160 | 11,228 | $7,747 |
| 2021-11 | 345,000 | $720,905 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-28 | Sherman Jeffrey W (Director) | Sale | 42,232 | 7.92 | 334,519 |
| 2025-08-28 | Sherman Jeffrey W (Director) | Option Ex | 47,040 | 6.66 | 313,286 |
| 2025-08-13 | Johnson John (Director) | Sale | 107,500 | 7.32 | 786,470 |
| 2025-08-12 | Halkuff Dawn (Director) | Sale | 42,500 | 7.28 | 309,230 |
| 2025-06-13 | Mcculloch Kevin (See Remarks) | Buy | 25,000 | 4.38 | 109,474 |
| 2025-03-20 | Hecht Beth (See Remarks) | Sale | 40,000 | 5.43 | 217,240 |
| 2024-11-22 | Pieper Steven (See Remarks) | Option Ex | 19,483 | 1.55 | 30,198 |
| 2024-08-12 | Schmid John P. (Director) | Buy | 4,515 | 2.25 | 10,145 |
| 2024-08-09 | Schmid John P. (Director) | Buy | 4,285 | 2.37 | 10,134 |
| 2024-05-10 | Schmid John P. (Director) | Buy | 5,400 | 1.91 | 10,314 |
| 2024-03-18 | Johnson John (Director) | Option Ex | 215,600 | 1.99 | 429,044 |
| 2024-03-14 | Schmid John P. (Director) | Buy | 4,500 | 2.16 | 9,720 |
| 2023-11-20 | Pieper Steven (See Remarks) | Buy | 28,000 | 1.95 | 54,600 |
| 2023-11-17 | Shannon John Patrick Jr (See Remarks) | Buy | 30,769 | 1.64 | 50,399 |
| 2023-11-16 | Schmid John P. (Director) | Buy | 6,500 | 1.51 | 9,815 |
| 2023-11-14 | Persky Marla (Director) | Buy | 6,370 | 1.58 | 10,058 |
| 2023-08-09 | Edick Paul R (See Remarks) | Buy | 10,000 | 2.38 | 23,790 |
| 2022-12-13 | Edick Paul R (See Remarks) | Buy | 20,000 | 1.45 | 29,000 |
| 2022-05-12 | Edick Paul R (See Remarks) | Buy | 100,000 | 1.40 | 140,400 |
| 2022-02-22 | Prestrelski Steven (Chief Scientific Officer) | Sale | 11,228 | 2.42 | 27,160 |
| 2022-02-22 | Prestrelski Steven (Chief Scientific Officer) | Option Ex | 11,228 | .69 | 7,747 |
| 2021-11-15 | Edick Paul R (See Remarks) | Buy | 20,000 | 2.28 | 45,660 |
| 2021-11-12 | Shannon John Patrick Jr (See Remarks) | Buy | 60,000 | 2.10 | 126,000 |
| 2021-11-11 | Shannon John Patrick Jr (See Remarks) | Buy | 40,000 | 2.09 | 83,520 |
| 2021-11-11 | Edick Paul R (See Remarks) | Buy | 200,000 | 2.08 | 415,800 |
| 2021-11-10 | Pieper Steven (See Remarks) | Buy | 25,000 | 2.00 | 49,925 |
Insider trading activities including stock purchases, stock sales, and option exercises of XERS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xeris Biopharma Holdings, Inc. (symbol XERS, CIK number 1867096) see the Securities and Exchange Commission (SEC) website.